HK1145677A1 - 取代的哌啶子基-二氫噻吩並嘧啶 - Google Patents

取代的哌啶子基-二氫噻吩並嘧啶

Info

Publication number: HK1145677A1
Authority: HK; Hong Kong
Prior art keywords: dihydrothienopyrimidines; substituted piperidino; piperidino; substituted; piperidino dihydrothienopyrimidines
Prior art date: 2007-10-19

Application number

HK10111978.1A

Other languages

English (en)

Inventor

Pascale Pouzet

Ralf Anderskewitz

Horst Dollinger

Dennis Fiegen

Thomas Fox

Rolf Goeggel

Christoph Hoenke

Domnic Martyres

Peter Nickolaus

Klaus Klinder

Original Assignee

貝林格爾．英格海姆國際有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-19

Filing date

2010-12-22

Publication date

2011-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1145677(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-12-22 Application filed by 貝林格爾．英格海姆國際有限公司 filed Critical 貝林格爾．英格海姆國際有限公司

2011-04-29 Publication of HK1145677A1 publication Critical patent/HK1145677A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK10111978.1A 2007-10-19 2010-12-22 取代的哌啶子基-二氫噻吩並嘧啶 HK1145677A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07118901		2007-10-19
PCT/EP2008/063999 WO2009050248A1 (de)	2007-10-19	2008-10-16	Substituierte piperidino-dihydrothienopyrimidine

Publications (1)

Publication Number	Publication Date
HK1145677A1 true HK1145677A1 (zh)	2011-04-29

Family

ID=39154006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK10111978.1A HK1145677A1 (zh)	2007-10-19	2010-12-22	取代的哌啶子基-二氫噻吩並嘧啶

Country Status (34)

Country	Link
US (1)	US8754073B2 (zh)
EP (3)	EP2610258B1 (zh)
JP (2)	JP5150728B2 (zh)
KR (1)	KR101548975B1 (zh)
CN (2)	CN104069112A (zh)
AR (1)	AR069075A1 (zh)
AT (1)	ATE542825T1 (zh)
AU (1)	AU2008313660B2 (zh)
BR (1)	BRPI0818006B8 (zh)
CA (1)	CA2705414C (zh)
CL (1)	CL2008003096A1 (zh)
CY (2)	CY1112703T1 (zh)
DK (2)	DK2215092T3 (zh)
EA (1)	EA019480B1 (zh)
EC (1)	ECSP10010156A (zh)
ES (2)	ES2524910T3 (zh)
HK (1)	HK1145677A1 (zh)
HR (2)	HRP20120334T1 (zh)
MA (1)	MA31845B1 (zh)
ME (1)	ME01330B (zh)
MX (1)	MX2010004026A (zh)
MY (1)	MY153979A (zh)
NZ (1)	NZ585346A (zh)
PE (2)	PE20131463A1 (zh)
PL (2)	PL2610258T3 (zh)
PT (2)	PT2215092E (zh)
RS (1)	RS52271B (zh)
SI (2)	SI2610258T1 (zh)
TN (1)	TN2010000175A1 (zh)
TW (1)	TWI421077B (zh)
UA (1)	UA99309C2 (zh)
UY (1)	UY31405A1 (zh)
WO (1)	WO2009050248A1 (zh)
ZA (1)	ZA201001683B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1847543A1 (de)	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
AU2008312624B2 (en) *	2007-10-18	2014-07-10	Boehringer Ingelheim International Gmbh	Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
US8637519B2 (en)	2007-10-19	2014-01-28	Boehringer Ingelheim International Gmbh	Heterocycle-substituted piperazino-dihydrothienopyrimidines
JP5563466B2 (ja)	2007-10-19	2014-07-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ピペラジノ−ジヒドロチエノピリミジン誘導体
KR101548975B1 (ko) *	2007-10-19	2015-09-01	베링거 인겔하임 인터내셔날 게엠베하	치환된 피페리디노-디하이드로티에노피리미딘
US9161927B2 (en)	2009-02-27	2015-10-20	Boehringer Ingelheim International Gmbh	Drug combinations containing PDE4 inhibitors and NSAIDs
EP2555774B1 (de)	2010-04-08	2015-10-21	Boehringer Ingelheim International GmbH	Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2011124524A1 (de)	2010-04-08	2011-10-13	Boehringer Ingelheim International Gmbh	Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2568812B1 (en) *	2010-05-11	2016-10-26	Merck Sharp & Dohme Corp.	Novel prolylcarboxypeptidase inhibitors
US20130059866A1 (en) *	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en)	2011-08-24	2017-10-31	Boehringer Ingelheim International Gmbh	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9013997B2 (en)	2012-06-01	2015-04-21	Broadcom Corporation	System for performing distributed data cut-through
US9422267B2 (en)	2012-12-26	2016-08-23	Medivation Technologies, Inc.	Fused pyrimidine compounds and use thereof
EP2951173B1 (en) *	2013-02-04	2017-05-17	Grünenthal GmbH	Novel substituted condensed pyrimidine compounds
WO2014124860A1 (en)	2013-02-14	2014-08-21	Boehringer Ingelheim International Gmbh	Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) *	2013-03-06	2014-09-29	Richter Gedeon Nyrt	Phenoxypiperidine h3 antagonists
CN104892720B (zh) *	2014-03-07	2016-10-26	华东师范大学	4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
AU2017288755B9 (en) *	2016-06-30	2021-08-19	Japanese Foundation For Cancer Research	Novel compound or pharmaceutically acceptable salt thereof
CN111108109A (zh) *	2017-09-20	2020-05-05	利奥制药有限公司	取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
CN111278442B (zh)	2017-10-23	2023-06-06	勃林格殷格翰国际有限公司	用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合
JP7201688B2 (ja) *	2017-12-15	2023-01-10	ユニオン・セラピューティクス・アクティエセルスカブ	置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
CN111727191B (zh)	2017-12-15	2024-01-05	联合疗法公司	取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
ES2968822T3 (es)	2017-12-15	2024-05-14	Union Therapeutics As	Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
WO2020048827A1 (en) *	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2023104958A1 (en)	2021-12-09	2023-06-15	Boehringer Ingelheim International Gmbh	New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
CA3236757A1 (en)	2021-12-09	2023-06-15	Boehringer Ingelheim International Gmbh	New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
TW202402289A (zh) *	2022-06-02	2024-01-16	大陸商西藏海思科製藥有限公司	Pde4b抑制劑及其用途
TW202408518A (zh) *	2022-06-16	2024-03-01	大陸商武漢人福創新藥物研發中心有限公司	Pde4b抑制劑
CN115040503B (zh) *	2022-07-26	2023-10-10	云南民族大学	螺环二烯酮型木脂素类化合物在制药中的应用
WO2024032673A1 (zh) *	2022-08-09	2024-02-15	西藏海思科制药有限公司	Pde4b抑制剂及其用途
WO2024068386A1 (en)	2022-09-28	2024-04-04	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
WO2024067660A1 (zh) *	2022-09-29	2024-04-04	苏州爱科百发生物医药技术有限公司	氮杂稠环类化合物、其制备方法及其在医药上的应用
WO2024179493A1 (zh) *	2023-02-28	2024-09-06	上海翊石医药科技有限公司	二氢噻吩并嘧啶衍生物的制备方法和用途
WO2024208225A1 (zh) *	2023-04-03	2024-10-10	上海壹迪生物技术有限公司	二氢噻吩并嘧啶类化合物、其制备方法和应用
WO2024213089A1 (zh) *	2023-04-13	2024-10-17	上海壹迪生物技术有限公司	取代的二氢噻吩并嘧啶类化合物、其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1470336A1 (de) *	1962-07-04	1969-03-20	Thomae Gmbh Dr K	Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (zh)	1963-06-17
DE1470356A1 (de)	1964-01-15	1970-04-30	Thomae Gmbh Dr K	Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (zh)	1965-03-31
DE1940572A1 (de)	1969-08-08	1971-02-11	Thomae Gmbh Dr K	Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en)	1970-07-02	1972-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) *	1969-08-08	1971-02-08	Thomae Gmbh Dr K	Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) *	1970-01-28	1973-10-02	Boehringer Sohn Ingelheim	2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (zh)	1970-03-18	1971-12-10	Westinghouse Freins & Signaux
DE2121950A1 (en)	1971-05-04	1972-11-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) *	1977-11-10	1979-05-17	Thomae Gmbh Dr K	Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) *	1979-06-11	1981-03-17	Syntex (U.S.A.) Inc.	Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) *	1991-10-24	1993-02-16	American Home Products Corporation	Substituted quinazolines as angiotensin II antagonists
US5491201A (en)	1992-02-06	1996-02-13	The Dow Chemical Company	Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja)	1994-06-08	1995-12-19	Taisho Pharmaceut Co Ltd	チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja)	1996-05-09	1997-11-25	Nippon Shoji Kk	新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en)	1997-08-13	2002-01-15	Fujirebio Inc.	Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
WO2001052902A1 (en)	2000-01-24	2001-07-26	Isis Pharmaceuticals, Inc.	Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
EP1326862B1 (de)	2000-10-12	2004-09-15	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10064994A1 (de)	2000-12-23	2002-07-04	Merck Patent Gmbh	Sulfamidothienopyrimidine
US6849638B2 (en)	2001-04-30	2005-02-01	Bayer Pharmaceuticals Corporation	4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
AR035700A1 (es)	2001-05-08	2004-06-23	Astrazeneca Ab	Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
IL159238A0 (en)	2001-06-22	2004-06-01	Boehringer Ingelheim Pharma	Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
US6587548B2 (en) *	2001-07-17	2003-07-01	Hewlett-Packard Development Co., L.P.	Method and system of using a single telephone number for multiple services
WO2003055890A1 (en)	2001-12-21	2003-07-10	Bayer Pharmaceuticals Corporation	Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
JP4505228B2 (ja)	2002-01-10	2010-07-21	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	Ｒｈｏ−キナーゼ阻害剤
SE0203304D0 (sv)	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Coumpounds
RS20050810A (en)	2003-04-29	2007-08-03	Pfizer Inc.,	5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
US20050084878A1 (en)	2003-05-16	2005-04-21	Wisconsin Alumni Research Foundation	Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja)	2003-05-21	2005-01-06	Showa Denko Kk	換気兼熱交換装置および空調システム
MX271416B (es) *	2003-10-02	2009-10-30	Martek Biosciences Corp	Produccion de altos niveles de dha en microalgas usando cantidades modificadas de cloruro y de potasio.
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en)	2003-12-18	2005-06-23	Abbott Gmbh & Co. Kg.	Tetrahydrobenzazepines and their use
JP4740152B2 (ja)	2003-12-23	2011-08-03	セロドスアクスイェセルスカブ	末梢性５−ｈｔ受容体の修飾因子
WO2005082865A1 (ja)	2004-02-27	2005-09-09	Astellas Pharma Inc.	縮合二環性ピリミジン誘導体
GB0427403D0 (en)	2004-12-15	2005-01-19	Astrazeneca Ab	Novel compounds I
KR20080005601A (ko)	2005-05-11	2008-01-14	니코메드 게엠베하	Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합
EP1847543A1 (de) *	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
PL1874781T3 (pl)	2006-04-19	2009-12-31	Boehringer Ingelheim Int	Dihydrotienopirymidyny do leczenia chorób zapalnych
MX2009011317A (es)	2007-04-20	2009-11-05	Glaxo Group Ltd	Compuestos que contienen nitrogeno triciclico como agentes antibacterianos.
AU2008312624B2 (en) *	2007-10-18	2014-07-10	Boehringer Ingelheim International Gmbh	Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
CL2008003085A1 (es)	2007-10-19	2009-10-09	Astrazeneca Ab	Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
US8637519B2 (en)	2007-10-19	2014-01-28	Boehringer Ingelheim International Gmbh	Heterocycle-substituted piperazino-dihydrothienopyrimidines
JP5563466B2 (ja)	2007-10-19	2014-07-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ピペラジノ−ジヒドロチエノピリミジン誘導体
FR2922550B1 (fr) *	2007-10-19	2009-11-27	Sanofi Aventis	Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
JP2011500621A (ja)	2007-10-19	2011-01-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
KR101548975B1 (ko)	2007-10-19	2015-09-01	베링거 인겔하임 인터내셔날 게엠베하	치환된 피페리디노-디하이드로티에노피리미딘
RU2010119635A (ru)	2007-10-19	2011-11-27	Шеринг Корпорейшн (US)	Соединения для ингибирования активности ksp кинезина
US9161927B2 (en) *	2009-02-27	2015-10-20	Boehringer Ingelheim International Gmbh	Drug combinations containing PDE4 inhibitors and NSAIDs
EP2400961B1 (de)	2009-02-27	2017-11-22	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
US20130059866A1 (en) *	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

2008
- 2008-10-16 KR KR1020107010905A patent/KR101548975B1/ko active IP Right Grant
- 2008-10-16 ME MEP-2012-26A patent/ME01330B/me unknown
- 2008-10-16 PT PT08839793T patent/PT2215092E/pt unknown
- 2008-10-16 MY MYPI2010001693A patent/MY153979A/en unknown
- 2008-10-16 UA UAA201005780A patent/UA99309C2/ru unknown
- 2008-10-16 BR BRPI0818006A patent/BRPI0818006B8/pt active IP Right Grant
- 2008-10-16 PL PL13154790T patent/PL2610258T3/pl unknown
- 2008-10-16 JP JP2010529389A patent/JP5150728B2/ja active Active
- 2008-10-16 PL PL08839793T patent/PL2215092T3/pl unknown
- 2008-10-16 NZ NZ585346A patent/NZ585346A/en unknown
- 2008-10-16 US US12/738,344 patent/US8754073B2/en active Active
- 2008-10-16 WO PCT/EP2008/063999 patent/WO2009050248A1/de active Application Filing
- 2008-10-16 RS RS20120144A patent/RS52271B/en unknown
- 2008-10-16 CA CA2705414A patent/CA2705414C/en active Active
- 2008-10-16 PT PT131547903T patent/PT2610258E/pt unknown
- 2008-10-16 DK DK08839793.0T patent/DK2215092T3/da active
- 2008-10-16 CN CN201410312258.5A patent/CN104069112A/zh active Pending
- 2008-10-16 AT AT08839793T patent/ATE542825T1/de active
- 2008-10-16 EP EP13154790.3A patent/EP2610258B1/de active Active
- 2008-10-16 DK DK13154790.3T patent/DK2610258T3/da active
- 2008-10-16 SI SI200831314T patent/SI2610258T1/sl unknown
- 2008-10-16 EP EP11174754.9A patent/EP2380891B1/de active Active
- 2008-10-16 SI SI200830579T patent/SI2215092T1/sl unknown
- 2008-10-16 AU AU2008313660A patent/AU2008313660B2/en active Active
- 2008-10-16 ES ES13154790.3T patent/ES2524910T3/es active Active
- 2008-10-16 EP EP08839793A patent/EP2215092B1/de active Active
- 2008-10-16 EA EA201000609A patent/EA019480B1/ru not_active IP Right Cessation
- 2008-10-16 ES ES08839793T patent/ES2381452T3/es active Active
- 2008-10-16 MX MX2010004026A patent/MX2010004026A/es active IP Right Grant
- 2008-10-16 CN CN200880112254.5A patent/CN101827852B/zh active Active
- 2008-10-17 UY UY31405A patent/UY31405A1/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104560A patent/AR069075A1/es active IP Right Grant
- 2008-10-17 PE PE2013001391A patent/PE20131463A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097139983A patent/TWI421077B/zh active
- 2008-10-17 PE PE2008001796A patent/PE20091386A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003096A patent/CL2008003096A1/es unknown
2010
- 2010-03-09 ZA ZA201001683A patent/ZA201001683B/xx unknown
- 2010-04-16 TN TN2010000175A patent/TN2010000175A1/fr unknown
- 2010-05-05 EC EC2010010156A patent/ECSP10010156A/es unknown
- 2010-05-12 MA MA32832A patent/MA31845B1/fr unknown
- 2010-12-22 HK HK10111978.1A patent/HK1145677A1/zh not_active IP Right Cessation
2012
- 2012-04-16 HR HRP20120334AT patent/HRP20120334T1/hr unknown
- 2012-04-23 CY CY20121100378T patent/CY1112703T1/el unknown
- 2012-12-03 JP JP2012264647A patent/JP5615889B2/ja active Active
2014
- 2014-11-26 CY CY20141100984T patent/CY1115858T1/el unknown
- 2014-11-26 HR HRP20141153AT patent/HRP20141153T1/hr unknown

Also Published As

Publication number	Publication date
CN101827852A (zh)	2010-09-08
UA99309C2 (ru)	2012-08-10
MX2010004026A (es)	2010-04-30
RS52271B (en)	2012-10-31
EP2610258B1 (de)	2014-08-27
MY153979A (en)	2015-04-30
BRPI0818006B8 (pt)	2021-05-25
MA31845B1 (fr)	2010-11-01
CY1112703T1 (el)	2016-02-10
PT2215092E (pt)	2012-04-10
HRP20120334T1 (hr)	2012-05-31
KR20100100807A (ko)	2010-09-15
JP5615889B2 (ja)	2014-10-29
UY31405A1 (es)	2009-05-29
EA019480B1 (ru)	2014-04-30
PT2610258E (pt)	2014-10-24
DK2215092T3 (da)	2012-05-07
HRP20141153T1 (hr)	2015-02-13
AR069075A1 (es)	2009-12-30
AU2008313660B2 (en)	2013-11-07
EP2380891A1 (de)	2011-10-26
TN2010000175A1 (fr)	2011-11-11
CA2705414C (en)	2016-05-24
SI2610258T1 (sl)	2014-12-31
CN101827852B (zh)	2014-07-30
SI2215092T1 (sl)	2012-04-30
NZ585346A (en)	2011-09-30
TW200918074A (en)	2009-05-01
PE20091386A1 (es)	2009-10-17
JP2011500640A (ja)	2011-01-06
PE20131463A1 (es)	2013-12-23
US8754073B2 (en)	2014-06-17
EP2610258A1 (de)	2013-07-03
EA201000609A1 (ru)	2010-10-29
CY1115858T1 (el)	2017-01-25
EP2215092B1 (de)	2012-01-25
KR101548975B1 (ko)	2015-09-01
BRPI0818006B1 (pt)	2019-10-22
JP5150728B2 (ja)	2013-02-27
DK2610258T3 (da)	2014-11-10
AU2008313660A1 (en)	2009-04-23
PL2610258T3 (pl)	2015-02-27
JP2013064001A (ja)	2013-04-11
ME01330B (me)	2013-12-20
ECSP10010156A (es)	2010-06-29
WO2009050248A1 (de)	2009-04-23
ES2524910T3 (es)	2014-12-15
CN104069112A (zh)	2014-10-01
TWI421077B (zh)	2014-01-01
US20110021501A1 (en)	2011-01-27
PL2215092T3 (pl)	2012-07-31
CL2008003096A1 (es)	2010-02-12
ATE542825T1 (de)	2012-02-15
ES2381452T3 (es)	2012-05-28
EP2215092A1 (de)	2010-08-11
CA2705414A1 (en)	2009-04-23
BRPI0818006A2 (pt)	2015-12-22
EP2380891B1 (de)	2013-12-11
ZA201001683B (en)	2010-10-27

Publication	Publication Date	Title
HK1145677A1 (zh)	2011-04-29	取代的哌啶子基-二氫噻吩並嘧啶
IL202616A0 (en)	2010-06-30	Substituted imidazoheterocycles
IL202666A0 (en)	2010-06-30	Substituted piperazines
HUE038157T2 (hu)	2018-09-28	Geoszõnyeg
GB0719108D0 (en)	2007-11-14	Coiloid-sensor
GB0708379D0 (en)	2007-06-06	Area-partitioning
GB0701437D0 (en)	2007-03-07	Electro-chlorinator
IL200965A0 (en)	2010-06-16	Substituted tetrahydropyrroloquinolines
GB0709749D0 (en)	2007-06-27	Juglr
ZA201000435B (en)	2010-10-27	Substituted imidazoheterocycles
GB0717492D0 (en)	2007-10-24	Turn case
GB0713975D0 (en)	2007-08-29	No Riveal
GB0714068D0 (en)	2007-08-29	No riveal
GB0710085D0 (en)	2007-07-04	I
GB0719462D0 (en)	2007-11-14	Bowthruster
GB0705839D0 (en)	2007-05-02	Wirebox
GB0721554D0 (en)	2007-12-12	Zippyship
GB0721150D0 (en)	2007-12-05	Vedawaves
GB0721891D0 (en)	2007-12-19	Fractillion
GB0725362D0 (en)	2008-02-06	Seaagull
GB0718322D0 (en)	2007-10-31	Breadmate
GB0715364D0 (en)	2007-09-19	Hitchlock
GB0715007D0 (en)	2007-09-12	Shopnav
GB0811216D0 (en)	2008-07-23	DataSitta
GB0713325D0 (en)	2007-08-22	Tri-pool

Legal Events

Date	Code	Title	Description
2019-05-24	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20181016